CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
108.24
+0.11 (+0.10%)
As of 4:00PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close108.13
Open108.01
Bid0.00 x 800
Ask0.00 x 4000
Day's Range107.27 - 108.59
52 Week Range58.59 - 110.70
Volume191,230,586
Avg. Volume7,971,330
Market Cap77.036B
Beta (3Y Monthly)N/A
PE Ratio (TTM)13.31
EPS (TTM)N/A
Earnings DateJan 29, 2020 - Feb 3, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est103.40
  • TheStreet.com

    Bristol-Myers Jumps After Celgene-Acquired Cancer Treatment Shows Promise

    Bristol-Myers shares edged higher Monday after the group said a new cancer treatment, which it acquired through its $74 billion takeover of Celgene Corp., had solid results from an early clinical trial. Bristol-Myers said a study presented to the American Society of Hematology Conference in Orlando, Florida showed a 53% complete response rate for patients with relapsed or refractory large B-cell lymphoma treated with liso-cel. The new treatment, a so-called chimeric antigen receptor T-cell, or " CAR-T" therapy, was acquired from the immunotherapy portfolio of Celgene last year.

  • Reuters

    Bristol-Myers reports positive data on cancer treatment acquired in Celgene deal

    Bristol-Myers Squibb Co on Saturday said that an experimental cancer therapy it acquired as part of its $74 billion deal for Celgene Corp produced positive results in a clinical trial. The company said it will apply for U.S. approval for the treatment for a type of advanced blood cancer by the end of the year. The treatment, liso-cel, is a newer type of immunotherapy known as CAR-T cell therapy, that takes immune cells from a patient, engineers them to better recognize and attack cancer and infuses them back into the patient.

  • Bloomberg

    Bluebird, Celgene Cancer Therapy Gets Boost From New Study

    (Bloomberg) -- An experimental therapy from Bluebird Bio Inc. and Bristol-Myers Squibb Co. benefited more than 80% of patients nearing death from an advanced form of blood cancer in a pivotal study, clearing a hurdle in its path to U.S. approval.A single high-dose infusion of the personalized medicine known as bb2121 generated a response in 44 of 54 patients with multiple myeloma, including 19 who had a complete response, the companies said in a statement Friday. Patients went a median of 11.3 months before the cancer progressed, topping expectations that it needed to stop the disease for at least six months to gain approval from the U.S. Food and Drug Administration.Bluebird shares briefly jumped in late trading on Friday before surrendering most of their gains. The recently-issued CVR given in connection with the closing of Bristol-Myers’ deal with Celgene, known by the ticker BMY-R, rose 8.3%.The companies divulged the findings on the eve of the American Society of Hematology’s annual meeting in Orlando, Florida, where GlaxoSmithKline Plc., Regeneron Pharmaceuticals Inc. and Bristol’s own Celgene unit will present data on competing approaches. Cambridge, Massachusetts-based Bluebird and New York-based Bristol-Myers are scheduled to give an update on their next-generation therapy, bb21217, on Monday, while hotly anticipated results from competitor Johnson & Johnson’s Nanjing Legend Biotech-partnered therapy will take the spotlight that morning.The depth and the durability of the data “puts us in very good stead around any of the antibodies as well as other gene therapies,” Bluebird Chief Executive Officer Nick Leschly said. “We feel quite good about it, and that’s why we’re sprinting toward submission and driving toward earlier lines of therapy.”Positive results from the study, dubbed KarMMa, could lead to the first approval of the approach called CAR-T for patients with multiple myeloma, a deadly form of cancer found in white blood cells, wrote Raju Prasad, an analyst at William Blair, in a note. A response rate greater than 80% that can hold off the disease for at least 11 months would be well-received by doctors who might otherwise be wary of potential high costs and an aggressive approach, said Yaron Werber, an analyst at Cowen & Co.The approach known as CAR-T is already approved for a hard-to-treat form of pediatric leukemia and diffuse large B cell lymphoma, both blood cancers that are much less common than the multiple myeloma, which is diagnosed in about 30,000 Americans each year. Bluebird and Bristol’s therapy involves removing infection-fighting T cells from the blood, altering them to recognize a protein known as BCMA that is found in multiple myeloma cells, then putting them back into the patient to kill the cancer.(Updates with stock-price movement in third paragraph)\--With assistance from Tatiana Darie.To contact the reporters on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.net;Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Mark Schoifet, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Moody's

    Bristol-Myers Squibb Company -- Moody's upgrades Celgene to A3

    Moody's Investors Service ("Moody's") upgraded the senior unsecured ratings of Celgene Corporation to A3 from Baa2. Moody's anticipates that the ratings of Celgene will eventually be withdrawn. The upgrade of the ratings follows the recent acquisition of Celgene by Bristol-Myers Squibb Company ("Bristol") in which Celgene became a subsidiary of Bristol.

  • Bristol-Myers Has Now Acquired Celgene — So, Should You Buy BMY Stock?
    Investor's Business Daily

    Bristol-Myers Has Now Acquired Celgene — So, Should You Buy BMY Stock?

    Pharmaceutical company Bristol-Myers has risen this year despite shareholder opposition to its Celgene buyout. Now that Bristol has officially acquired Celgene, is it time to buy BMY stock?

  • $50M deal could expand NanoString Technologies diagnostic test into more markets
    American City Business Journals

    $50M deal could expand NanoString Technologies diagnostic test into more markets

    NanoString, which creates devices for molecular diagnostics and research tools to understand diseases and develop drugs, will record more than $100 million in revenue this year.

  • Looking For Growth? Take A Look At These Biotechnology Stocks
    Investor's Business Daily

    Looking For Growth? Take A Look At These Biotechnology Stocks

    The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.

  • Bristol-Myers Squibb Charts Prescribe Optimism in the Months Ahead
    TheStreet.com

    Bristol-Myers Squibb Charts Prescribe Optimism in the Months Ahead

    There may be sideways action in the drugmaker's shares in the near term, but a strong move higher is possible down the road.

  • Here is the 17th Most Popular Stock Among 752 Hedge Funds
    Insider Monkey

    Here is the 17th Most Popular Stock Among 752 Hedge Funds

    The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]

  • Benzinga

    The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More

    Biotech stocks experienced some momentum last week amid a few clinical readouts. Karuna Therapeutics Inc (NASDAQ: KRTX ), which went public in June, was among the biggest gainers of the week on a  positive ...

  • Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Deal
    Zacks

    Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Deal

    Bristol-Myers' (BMY) late-stage study evaluating the Opdivo-Yervoy combo fails to meet a co-primary endpoint of recurrence-free survival in melanoma patients. The company wraps up Celgene acquisition.

  • Barrons.com

    Bristol-Myers’ Binary Bet on Celgene Drugs Makes a Splash in Debut

    The contingent value rights debuted with a bang on the New York Stock Exchange Thursday, with heavy trading volume of 101 million amid selling by index funds.

  • Amgen Wraps Otezla Takeover — And Other Fallout From BMY's Celgene Buy
    Investor's Business Daily

    Amgen Wraps Otezla Takeover — And Other Fallout From BMY's Celgene Buy

    Amgen raised its full-year outlook Thursday after the biotech company wrapped its acquisition of psoriasis treatment Otezla in the wake of Bristol-Myers Squibb's takeover of Celgene.

  • Top Health Care Stocks for December 2019
    Investopedia

    Top Health Care Stocks for December 2019

    These are the health care stocks with the best value, fastest growth, and most momentum for December.

  • Biotech ETF (BBH) Hits New 52-Week High
    Zacks

    Biotech ETF (BBH) Hits New 52-Week High

    This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?

  • Reuters

    Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug

    Amgen Inc on Thursday raised its full-year profit and revenue forecasts after completing its $13.4 billion acquisition of Celgene Corp's psoriasis therapy Otezla. Bristol-Myers Squibb Co, which completed its buyout of Celgene on Wednesday, had agreed to divest the drug for the merger to go through. Amgen now expects 2019 adjusted earnings per share between $14.50 and $14.70, up from its prior range of $14.20 to $14.45.

  • PR Newswire

    Amgen Completes Acquisition Of Otezla® (apremilast)

    THOUSAND OAKS, Calif., Nov. 21, 2019 /PRNewswire/ -- Amgen (AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis. Otezla was acquired from Celgene Corporation (CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (BMY), which was completed on Nov. 20. Otezla is an important treatment in the post-topical, pre-biologic segment in its approved indications in the U.S., including the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy; adult patients with active psoriatic arthritis; and adult patients with oral ulcers associated with Behçet's Disease.

  • TheStreet.com

    Bristol-Myers Closes $74 Billion Celgene Takeover; Shares Gain

    Bristol-Myers Squibb shares edged higher Thursday after the pharmaceutical group said it has completed its $74 billion acquisition of cancer drug specialist Celgene Corp.

  • Barrons.com

    An All-or-Nothing Bet on 3 Drugs in Celgene’s Pipeline

    A new security issued as part of the deal with Bristol-Myers Squibb amounts to potentially lucrative lottery ticket.

  • MarketWatch

    Bristol-Myers Squibb completes $74 billion acquisition of Celgene

    Bristol-Myers Squibb Co. on Wednesday said it completed its $74 billion acquisition of Celgene Corp. , nearly a year after announcing the controversial deal. The completion comes after the Federal Trade Commission cleared the merger in a statement on Friday. The FTC required Bristol-Myers and Celgene sell the rights to Otezla, Celgene's psoriasis drug. Amgen Inc. agreed to buy the rights to the drug for $13.4 billion in August. Shares of Bristol-Myers and Celgene are up slight in after-hours trading on Wednesday.

  • Barrons.com

    At Long Last, Bristol-Myers Buys Celgene

    (BMY)announced Wednesday that it had completed its acquisition of the biotech firm Celgene, nearly a year after announcing the controversial deal. The completion comes after the Federal Trade Commission effectively cleared the merger in a statement on Friday. As a condition of the deal, the FTC required Bristol-Myers (ticker: BMY) and Celgene (CELG) to sell the rights to Otezla, Celgene’s psoriasis drug.

  • Business Wire

    Celgene Announces Plans to Transfer Listing of Celgene’s Contingent Value Rights Following Closing of Acquisition by Bristol-Myers Squibb

    Celgene Corporation announced today that following the completion of Celgene’s acquisition by Bristol-Myers Squibb Company , Bristol-Myers Squibb and Celgene plan to transfer the listing of Celgene’s contingent value rights that are related to Celgene’s ABRAXANE® product from the NASDAQ Global Market to the New York Stock Exchange .

  • Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More
    Zacks

    Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More

    Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

  • Top Ranked Growth Stocks to Buy for November 20th
    Zacks

    Top Ranked Growth Stocks to Buy for November 20th

    Top Ranked Growth Stocks to Buy for November 20th

  • PR Newswire

    Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500

    NEW YORK , Nov. 19, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO) will replace Celgene Corp. (NASD: CELG) in the S&P 100, and ServiceNow Inc. (NYSE: NOW) will replace Celgene in the S&P ...